| Study |
Treatment regiment |
Follow up period (months) |
Results |
Ref |
| TAP |
*v-PDT |
24 |
V-PDT reduced the risk of moderate or severe vision loss in patients with CNV due to AMD. |
[3] |
| VIP |
*v-PDT |
24 |
In the v-PDT group, VA improvement by at least 5 letters was observed in patients with CNV due to pathologic myopia. |
[42] |
| Lam et al. |
*v-PDT (Asian patients) |
24 |
Median VA improvement was 1.7 lines, but the mean number of PDT retreatments required in the first 2 years was 2.3-lower than in the VIP study. |
[43] |
| VISION |
pegaptanib sodium (0.3 mg) |
12 |
70% of patients lost fewer than 15 letters of visual acuity, as compared with 55% among the controls. Improvement in mean visual acuity was not observed. |
[115] |
| ANCHOR |
ranibizumab (0.3 mg or 0.5 mg) vs.
*v-PDT |
12 |
Ranibizumab was clearly superior to PDT with Respect to both visual acuity (VA) and anatomic (lesion size and CNV leakage) efficacy outcomes. |
[41] |
| FOCUS |
ranibizumab 0.5 mg monthly or sham injections monthly followed by *v-PDT at day zero |
24 |
Combination therapy was more effective than v-PDT alone and had a low rate of adverse events. |
[116] |
| PROTECT |
same-day *v-PDT and ranibizumab 0.5 mg in CNV AMD |
12 |
Improved VA, lesions were stabilized with minimal treatment required after month 3. |
[117] |
| MONT BLANC |
*v-PDT, ranibizumab 0.5 mg
In CNV AMD |
12 |
VA improvements in the combination group are non-inferior to a ranibizumab alone with three ranibizumab doses followed by injections on a monthly regimen. |
[118] |
| DENALI |
*v-PDT+ranibizumab 0.5 mg,
**reduced fluence v-PDT
+ranibizumab 0.5 mg,
ranibizumab 0.5 mg
In CNV AMD |
12 |
DENALI did not demonstrate non-inferior visual acuity gain for v-PDT combination therapy compared with ranibizumab monthly monotherapy. |
[120] |
| EVEREST |
*v-PDT+ranibizumab 0.5 mg in PCV |
12 |
Complete regression of polypoidal lesions in combination therapy group. |
[119] |
| RADICAL |
**v-PDT+within 2 h ranibizumab (0.5mg)+dexamethasone (0.5 mg); vs.
***v-PDT
+ ranibizumab (0.5 mg)
+ dexamethasone (0.5 mg); vs.
ranibizumab only (0.5 mg) |
24 |
Cumulative retreatment rates were lower in all combination groups compared with the ranibizumab monotherapy group. Mean VA change from baseline was not statistically different among the treatment groups. |
[126] |
| VALIO |
*v-PDT
(light applied 30 minutes after the start of verteporfin infusion) |
12 |
Improved VA and angiographic outcomes with an acceptable safety profile compared with standard light application 15 minutes after the start of the infusion |
[152] |
TRIPLE
THERAPY |
**v-PDT, 16 h later, dexamethasone (800 μg) and bevacizumab (1.5 mg) |
9 |
Less than 25% of the patients treated with this regimen required additional treatment. |
[127] |
| *v-PDT+immediate injection of bevacizumab (1.25 mg)+TA (4 mg)+bevacizumab (1.25 mg) every 3 months |
6 |
Short-term results of this study (at 6 months) showed low rate of retreatments, sustained CNV closure efficacy and visual acuity improvement. |
[128] |
| |
Same-day **v-PDT
+ dexamethasone (200 μg)
+ bevacizumab (1.5 mg) |
13.7 |
VA was maintained, decreased macular thickness in treatment-naïve or previously treated with anti-VEGF.
The mean number of repeat triple therapy treatments was 0.3 in both mentioned groups. |
[129] |
CFT: Choroidal foveal thickness; PCV: polyploidal choroidal vasculopathy;